Long-term safety and efficacy of efgartigimod in generalized myasthenia gravis during the ADAPT+ study
Background: Efgartigimod is a human immunoglobulin G1 (IgG1) antibody Fc-fragment that reduces total and pathogenic IgG autoantibody levels through neonatal Fc receptor blockade. ADAPT was a 26-week, global, multicenter, randomized, placebo-controlled, phase 3 trial evaluating efgartigimod in participants with generali...